|
COVID-19 (+)
n=46
|
COVID-19 (-)
n=45
|
p value
|
Age (years) |
46.5 (36.8-55.0) |
37.0 (32.0-55.0) |
0.194 |
Male, n (%) |
32 (69.6) |
27 (60.0) |
0.231 |
Etiology of CKD |
Etiology of CKD |
Etiology of CKD |
Etiology of
CKD |
Diabetes Mellitus, n (%) |
5 (10.9) |
3 (6.7) |
0.599 |
Glomerulonephritis, n (%) |
8 (17.4) |
11 (24.4) |
|
Others, n (%) |
33 (71.7) |
31 (68.9) |
|
Living donor, n (%) |
36 (78.3) |
35 (77.8) |
0.600 |
Transplantation Duration (months) |
108.0 (48.0-147.0) |
84.0
(24.0-132.0) |
0.378 |
COVID-19 in a household member, n (%) |
29 (64.4) |
3 (6.8) |
<0.001 |
Comorbidities |
Comorbidities |
Comorbidities |
Comorbidities |
Diabetes, n (%) |
13 (28.3) |
11 (24.4) |
0.431 |
Hypertension, n (%) |
31 (67.4) |
26 (57.8) |
0.232 |
BMI (kg/m2) |
27.4 ± 4.5 |
24.7 ± 4.2 |
0.004 |
Serum Creatinine (mg/dL) |
1.28 (1.01-1.53) |
1.23 (1.02-1.72) |
0.778 |
e-GFR† (ml/min/1.73 m2) |
64.9 ± 24.1 |
64.6 ± 31.6 |
0.955 |
Baseline immunosuppression |
Baseline immunosuppression |
Baseline
immunosuppression |
Baseline immunosuppression |
Steroids, n (%) |
46 (100.0) |
42 (93.3) |
0.117 |
Calcineurin inhibitor, n (%) |
43 (93.5) |
43 (95.6) |
0.511 |
Mycophenolic acid derivates, n (%) |
41 (89.1) |
35 (77.8) |
0.119 |
m-TOR inhibitors, n (%) |
4 (8.7) |
4 (8.9) |
0.631 |
Azathioprine, n (%) |
3 (6.5) |
7 (15.6) |
0.149 |